Pharmacokinetics, pharmacodynamics and tolerability of multiple oral doses of linagliptin, a dipeptidyl peptidase-4 inhibitor in male type 2 diabetes patients.
about
Pharmacokinetic and pharmacodynamic evaluation of linagliptin for the treatment of type 2 diabetes mellitus, with consideration of Asian patient populationsRole of dipeptidyl peptidase-4 inhibitors in new-onset diabetes after transplantationThe clinical application of linagliptin in AsiansLinagliptin improves insulin sensitivity and hepatic steatosis in diet-induced obesityEffects of DPP-4 inhibitors on the heart in a rat model of uremic cardiomyopathyCardiovascular Safety of Dipeptidyl-Peptidase IV Inhibitors: A Meta-Analysis of Placebo-Controlled Randomized Trials.Metrics for glycaemic control - from HbA1c to continuous glucose monitoring.Challenges in achieving optimal glycemic control in type 2 diabetes patients with declining renal function: The Southeast Asia perspectiveThe evolving place of incretin-based therapies in type 2 diabetesPharmacokinetics of afatinib in subjects with mild or moderate hepatic impairment.Safety and tolerability of linagliptin: a pooled analysis of data from randomized controlled trials in 3572 patients with type 2 diabetes mellitus.Clinical pharmacokinetics and pharmacodynamics of linagliptin.Recognition, pathogenesis, and treatment of different stages of nephropathy in patients with type 2 diabetes mellitusDipeptidyl peptidase-4 inhibitors in the management of type 2 diabetes: safety, tolerability, and efficacy.The DPP-4 inhibitor linagliptin does not prolong the QT interval at therapeutic and supratherapeutic doses.Cardiovascular safety of linagliptin in type 2 diabetes: a comprehensive patient-level pooled analysis of prospectively adjudicated cardiovascular eventsEfficacy and safety of linagliptin (tradjenta) in adults with type-2 diabetes mellitus.Population Pharmacokinetics and Pharmacodynamics of Linagliptin in Patients with Type 2 Diabetes Mellitus.Pharmacokinetics of linagliptin in subjects with hepatic impairmentPotential role of linagliptin as an oral once-daily treatment for patients with type 2 diabetes.Linagliptin for type 2 diabetes mellitus: a review of the pivotal clinical trials.Linagliptin increases incretin levels, lowers glucagon, and improves glycemic control in type 2 diabetes mellitus.Emerging DPP-4 inhibitors: focus on linagliptin for type 2 diabetesLong-term efficacy and safety of linagliptin in patients with type 2 diabetes and severe renal impairment: a 1-year, randomized, double-blind, placebo-controlled studyLinagliptin: A thorough Characterization beyond Its Clinical EfficacySafety and efficacy of linagliptin in type 2 diabetes patients with common renal and cardiovascular risk factors.Alternate-day dosing of linagliptin in type 2 diabetes patients controlled on once daily dose: A case series.Pharmacokinetic and pharmacodynamic evaluation of linagliptin in African American patients with type 2 diabetes mellitus.Comparable pharmacodynamics, efficacy, and safety of linagliptin 5 mg among Japanese, Asian and white patients with type 2 diabetesDesign, statistical analysis and sample size calculation of a phase IIb/III study of linagliptin versus voglibose and placebo.Linagliptin, a xanthine-based dipeptidyl peptidase-4 inhibitor with an unusual profile for the treatment of type 2 diabetes.Linagliptin: in type 2 diabetes mellitus.Small molecule dipeptidylpeptidase IV inhibitors under investigation for diabetes mellitus therapy.Linagliptin: a novel dipeptidyl peptidase 4 inhibitor with a unique place in therapy.Linagliptin: a new DPP-4 inhibitor for the treatment of type 2 diabetes mellitus.Pharmacology of dipeptidyl peptidase-4 inhibitors: similarities and differences.Linagliptin for the treatment of type 2 diabetes (pharmacokinetic evaluation).Linagliptin, a dipeptidyl peptidase-4 inhibitor with a unique pharmacological profile, and efficacy in a broad range of patients with type 2 diabetes.Pharmacology, efficacy, and safety of linagliptin for the treatment of type 2 diabetes mellitus.Differentiating among incretin therapies: a multiple-target approach to type 2 diabetes.
P2860
Q26749524-3B2F8DFD-5AE4-4BA5-997E-FB56439AB193Q26778329-5B6FBD44-4EB2-4BF6-B74C-46A66F40DAA6Q26781942-0C8751D1-681B-47E7-ADB9-4265897638B5Q28728101-B0A571B1-5F88-4DAA-A999-D8062AD99E03Q28742534-302703B3-E67D-46A9-B84D-D41A0FA1DA3AQ30240823-16D6F08A-12DC-428F-B7B3-2C0D462A0DC7Q30252932-3F9D90E4-A2AA-44ED-AB48-39F8A70B21C5Q33587783-644D88A6-F2F6-4B35-B4F6-11625109B051Q33866808-F0DB5F38-F02F-44D6-80EF-A5B9FD6F45AAQ33954583-FA546C06-986B-4C53-B8D4-A2501F6243DDQ34135837-3E90BD40-9223-421D-B786-3C0B2124B6F9Q34638128-EC2CC694-D7E0-4322-9FBA-A4F5E7381E44Q34887952-CF4168B7-F708-4B4A-BF91-2CAB7BA51830Q35026483-B74061A0-65C4-4889-8577-C7F68B4E6FFEQ35120585-A8A27D92-0403-4C28-AC57-36A3C37AA997Q35736564-3354DEB7-690A-40D5-B745-912DDF9588F8Q35752928-96C09359-7751-4D37-8F0E-33A69058C297Q35800419-474186B4-DDEB-4168-AF81-5D97B6DDD2AFQ36087961-1EE98F1D-6C45-40DB-B7DA-C5C7BEA65110Q36196649-2E97A3A6-4858-4E5C-AD2D-50DE079D59CCQ36401258-52422F24-F2BF-4C26-8868-4C11506A8B38Q36428096-B43FC165-4FC9-47C8-A022-E53D0E61A70DQ36520758-9E601D38-7BB5-4F09-B5CB-43685963AA33Q36560252-5ED79194-F083-4D5E-8D49-94183FE1B357Q36636639-E77DC109-693A-40BD-8163-9C89F3F38661Q36883337-A72732DB-13FA-4BF2-9E8E-5561FF8AD13AQ37015654-F5FA1096-00EF-467C-9E3F-650907B9D683Q37161909-64448210-149D-4552-87E6-7999997078ECQ37227407-D5E7B5F0-03D0-4047-AD0B-246A0F5DD1CFQ37346130-C9CD115C-F8CF-4B8E-B7C4-FA606C151CAFQ37641377-43F8ECA2-BCF4-4F11-99D8-FE192CF154F2Q37858521-BA87D5DA-FE44-42A1-A4F8-E7B4FAF7DE19Q37866299-52F63434-195E-41C8-B47D-CC01288F9BC2Q37878396-27A0EDC4-47B0-41D8-B587-4CD02B3BD68AQ37890779-D1309DE8-F296-40B9-952F-34587A6BF61BQ37910902-A906CBCD-3654-4A4E-B0A3-C9ECA33F9373Q37948831-D9387F7C-0468-4D79-9D6F-1BE43256689EQ37965613-0DFA00F8-FC6F-4979-BBFD-26F3A41DA0ADQ37982680-36EF40D1-FC31-4B10-8C6B-41AC5B98AC18Q37995760-C005E216-5703-4557-8F1E-7BEEC926DE78
P2860
Pharmacokinetics, pharmacodynamics and tolerability of multiple oral doses of linagliptin, a dipeptidyl peptidase-4 inhibitor in male type 2 diabetes patients.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh-hant
name
Pharmacokinetics, pharmacodyna ...... male type 2 diabetes patients.
@en
Pharmacokinetics, pharmacodyna ...... male type 2 diabetes patients.
@nl
type
label
Pharmacokinetics, pharmacodyna ...... male type 2 diabetes patients.
@en
Pharmacokinetics, pharmacodyna ...... male type 2 diabetes patients.
@nl
prefLabel
Pharmacokinetics, pharmacodyna ...... male type 2 diabetes patients.
@en
Pharmacokinetics, pharmacodyna ...... male type 2 diabetes patients.
@nl
P2093
P921
P1476
Pharmacokinetics, pharmacodyna ...... male type 2 diabetes patients.
@en
P2093
D Trommeshauser
E U Graefe-Mody
P304
P356
10.1111/J.1463-1326.2009.01046.X
P577
2009-05-19T00:00:00Z